Literature DB >> 7514247

Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56).

J F Seymour1, S A Pierce, H M Kantarjian, M J Keating, E H Estey.   

Abstract

The mechanisms of extramedullary leukemic infiltration are not well characterized. The cell-surface glycoprotein CD56, which is identical to the neural cell adhesion molecule, may be involved. Using the Leu-19 antibody and flow cytometric methods, the leukemic blasts of 22% (70 of 314) of patients were CD56 positive. This was most common in acute monocytic leukemia (15 of 18, 83%) and in patients with the cytogenetic abnormalities t(8;21) (seven of 13, 54%) and trisomy 8 (nine of 22, 41%). CD56 expression was not associated with extramedullary leukemic infiltration, but was correlated with positivity for CD11b (p < 0.001), CD14 (p < 0.001) and CD19 (p = 0.018). Although associated with morphologic and cytogenetic features, CD56 expression alone cannot account for most instances of tissue infiltration in acute myeloid leukemia (AML).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514247

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

1.  CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy.

Authors:  Lars Fischer; Nicola Gökbuget; Stefan Schwartz; Thomas Burmeister; Harald Rieder; Monika Brüggemann; Dieter Hoelzer; Eckhard Thiel
Journal:  Haematologica       Date:  2008-12-23       Impact factor: 9.941

2.  Erythroblastic sarcoma presenting as bilateral ovarian masses in an infant with pure erythroid leukemia.

Authors:  Huan-You Wang; Lily Jun-shen Huang; Zhaoli Liu; Rolando Garcia; Shiyong Li; Carlos A Galliani
Journal:  Hum Pathol       Date:  2011-01-15       Impact factor: 3.466

3.  The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0.

Authors:  Ritsuro Suzuki; Shigeki Ohtake; Jin Takeuchi; Masami Nagai; Yoshihisa Kodera; Motohiro Hamaguchi; Shuichi Miyawaki; Takahiro Karasuno; Shigetaka Shimodaira; Ryuzo Ohno; Shigeo Nakamura; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-01-29       Impact factor: 2.490

4.  CD56/NCAM-positive Langerhans cell sarcoma: a clinicopathologic study of 4 cases.

Authors:  Takakazu Kawase; Minoru Hamazaki; Michinori Ogura; Yoshiaki Kawase; Toshihiko Murayama; Yoshio Mori; Hirokazu Nagai; Masatoshi Tateno; Takashi Oyama; Yoshikazu Kamiya; Hirofumi Taji; Yoshitoyo Kagami; Tomoki Naoe; Toshitada Takahashi; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2005-05       Impact factor: 2.490

5.  Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0.

Authors:  Ritsuro Suzuki; Makoto Murata; Masahiro Kami; Shigeki Ohtake; Norio Asou; Yoshihisa Kodera; Masao Tomonaga; Yasufumi Masaki; Shuya Kusumoto; Jin Takeuchi; Shin Matsuda; Hisamaru Hirai; m Seiichi Yorimitsu; Nobuyuki Hamajima; Masao Seto; Masanori Shimoyama; Ryuzo Ohno; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

6.  Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia.

Authors:  Brian A Webber; Melissa M Cushing; Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

7.  Leukemia cutis in a patient with acute monocytic leukemia diagnosed simultaneously with hepatocellular carcinoma: A case study.

Authors:  Dong Keun Seok; Sae Yoon Kee; Soon Young Ko; Jung Hwa Lee; Hye Young Kim; In Sun Kim; Hee Yeon Seo
Journal:  Oncol Lett       Date:  2013-09-12       Impact factor: 2.967

8.  Central nervous system involvement in patients with acute myeloid leukemia

Authors:  Hatime Arzu Yaşar; Olgu Erkin Çinar; Nur Yazdali Köylü; Ibrahim Barişta; Hakan Göker; Yahya Büyükaşik
Journal:  Turk J Med Sci       Date:  2021-10-21       Impact factor: 0.973

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.